JOINT FILING AGREEMENTJoint Filing Agreement • January 20th, 2023 • Dialectic Capital Management, Lp • In vitro & in vivo diagnostic substances
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001par value per share, of Achieve Life Sciences, Inc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
